Trial reportChest2014
Effect of isoniazid therapy for latent TB infection on QuantiFERON-TB gold in-tube responses in adults with positive tuberculin skin test results in a high TB incidence area: a controlled study.
Trial report in Chest, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01119521 (Phase I Study of Whether Preclearance of Latent M. Tuberculosis), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I Study of Whether Preclearance of Latent M. Tuberculosis (MTB) Infection With Isoniazid (INH) Enhances Specific Immune Responses to MTB Following Subsequent BCG Revaccination in Healthy, HIV-Uninfected, Tuberculin Skin Test Positive Adults
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review.Revista da Sociedade Brasileira de Medicina Tropical · 2024Pooled it
- Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses.Journal of immunology (Baltimore, Md. : 1950) · 2016Trial
- Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study.BMC infectious diseases · 2015Trial
- Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis.The European respiratory journal · 2015Trial
- Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.Vaccine · 2014Trial
- Trial
- Comparative agreement between tuberculin skin test and QuantiFERON-TB Gold In-Tube across different levels of exposure in a college-based tuberculosis outbreak.Frontiers in public health · 2026Article
- Metformin Increases Cell Viability and Regulates Pro-Inflammatory Response to Mtb.Infection and drug resistance · 2023Article
- Granulomatous Cheilitis or Tuberculid?Antibiotics (Basel, Switzerland) · 2022Article
- Circulating mitochondrial cell-free DNA dynamics in patients with mycobacterial pulmonary infections: Potential for a novel biomarker of disease.Frontiers in immunology · 2022Article
- Article
- Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease.Tuberculosis (Edinburgh, Scotland) · 2021Article
- Tuberculosis Infection in Women of Reproductive Age: A Cross-sectional Study at Antenatal Care Clinics in an Ethiopian City.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Clinical application of QuantiFERON-TB Gold in-tube in the diagnosis and treatment of tuberculosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Review
- Diagnosis for Latent Tuberculosis Infection: New Alternatives.Frontiers in immunology · 2020Review
- Discovery of Potential Plasma Biomarkers for Tuberculosis in HIV-Infected Patients by Data-Independent Acquisition-Based Quantitative Proteomics.Infection and drug resistance · 2020Article
- Article
- Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy.Scientific reports · 2019Article
- Expression of USP18 and IL2RA Is Increased in Individuals Receiving Latent Tuberculosis Treatment with Isoniazid.Journal of immunology research · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundT-cell interferon-γ release assays (IGRAs) are used in the diagnosis of Mycobacterium tuberculosis infection and could be useful biomarkers of response to treatment of latent TB infection for clinical trials, infection control units, and TB programs.
methodsThis investigation was a prospective, controlled substudy of IGRA responses in 82 healthy South African adults with HIV seronegative and positive tuberculin skin test results randomly assigned to treatment with 6 months of daily isoniazid preventive therapy (IPT) or observation before Bacillus Calmette-Guérin revaccination in a clinical trial. QuantiFERON-TB Gold In-Tube (QFT-GIT) assay was used to measure interferon-γ (IFN-γ) response to mycobacterial antigens at baseline and after IPT or observation.
resultsIFN-γ levels declined between baseline and the end of IPT (signed rank test P≤.0001) and between baseline and a similar period of observation without IPT (signed rank test P=.03). The rate of decrease in IFN-γ responses over time did not differ between the groups (Mann-Whitney-Wilcoxon test P=.31). QFT-GIT test results in two subjects (5%) in the IPT group and two subjects (5%) in the observation group reverted from positive to negative during follow-up. No significant difference was found between the groups with respect to baseline positivity or the proportion of patients whose tests reverted to negative.
conclusionsIPT had no effect on changes in QFT-GIT readouts during short-term follow-up of adults with positive tuberculin skin tests in a high TB incidence setting. QFT-GIT is unlikely to be a useful biomarker of response to treatment of latent TB infection. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01119521; URL: www.clinicaltrials.gov.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.